BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23084012)

  • 1. Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer.
    Pou Ucha JL; Nogueiras Alonso JM; Alvarez Paez AM; Suarez Arfenoni BA; Puig AS; Lopez Lopez AM; Barandela Salgado J; Campos Villarino LM; Casal Rivas M; Guitian Iglesias R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):301-7. PubMed ID: 23084012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
    Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
    Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
    Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
    Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
    Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
    Meng X; Sun X; Mu D; Xing L; Ma L; Zhang B; Zhao S; Yang G; Kong FM; Yu J
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):960-6. PubMed ID: 21440998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
    Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
    Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Would you bet on PET? Evaluation of the significance of positive PET scan results post-microwave ablation for non-small cell lung cancer.
    Zaheer SN; Whitley JM; Thomas PA; Steinke K
    J Med Imaging Radiat Oncol; 2015 Dec; 59(6):702-12. PubMed ID: 26041618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of lung cancer after radiofrequency ablation detected by PET/CT and contrast enhanced CT scan.
    Scappaticci AA; Yoo DC
    Med Health R I; 2012 May; 95(5):146-8. PubMed ID: 22808632
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
    Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
    J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.
    Chiu CH; Yeh YC; Lin KH; Wu YC; Lee YC; Chou TY; Tsai CM
    J Thorac Oncol; 2011 Oct; 6(10):1697-703. PubMed ID: 21869716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer.
    Koizumi T; Tsushima K; Tanabe T; Agatsuma T; Yokoyama T; Ito M; Kanda S; Kobayashi T; Yasuo M
    Respiration; 2015; 90(1):47-55. PubMed ID: 26044954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?
    Yoo DC; Dupuy DE; Hillman SL; Fernando HC; Rilling WS; Shepard JA; Siegel BA
    AJR Am J Roentgenol; 2011 Aug; 197(2):334-40. PubMed ID: 21785078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual time-point (18)F-FDG PET/CT to assess response to radiofrequency ablation of lung metastases.
    Lafuente S; Fuster D; Arguis P; Granados U; Perlaza P; Paredes P; Vollmer I; Sánchez M; Lomeña F
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):226-31. PubMed ID: 26848142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.